
Immatics N.V. – NASDAQ:IMTX
Immatics N.V. stock price today
Immatics N.V. stock price monthly change
Immatics N.V. stock price quarterly change
Immatics N.V. stock price yearly change
Immatics N.V. key metrics
Market Cap | 828.33M |
Enterprise value | 242.54M |
P/E | 11 |
EV/Sales | 1.60 |
EV/EBITDA | 5.62 |
Price/Sales | 2.27 |
Price/Book | 3.04 |
PEG ratio | 0.15 |
EPS | -0.98 |
Revenue | 74.64M |
EBITDA | -68.81M |
Income | -80.31M |
Revenue Q/Q | 210.81% |
Revenue Y/Y | -6.36% |
Profit margin | 22.5% |
Oper. margin | 9.18% |
Gross margin | 0% |
EBIT margin | 9.18% |
EBITDA margin | -92.18% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmatics N.V. stock price history
Immatics N.V. stock forecast
Immatics N.V. financial statements
Jun 2023 | 22.35M | -24.61M | -110.09% |
---|---|---|---|
Sep 2023 | 5.92M | -26.48M | -447% |
Dec 2023 | 15.92M | -26.14M | -164.24% |
Mar 2024 | 30.44M | -3.07M | -10.09% |
2025 | 53.21M | -119.88M | -225.3% |
---|---|---|---|
2026 | 45.22M | -150.01M | -331.72% |
2027 | 62.80M | -93.26M | -148.51% |
2028 | 111.35M | -81.66M | -73.33% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 410189000 | 191.97M | 46.8% |
---|---|---|---|
Sep 2023 | 437450000 | 189.69M | 43.36% |
Dec 2023 | 509965000 | 284.88M | 55.86% |
Mar 2024 | 653730305 | 252.57M | 38.64% |
Jun 2023 | -6.60M | -16.83M | 36.45M |
---|---|---|---|
Sep 2023 | -30.52M | -70.57M | 49.90M |
Dec 2023 | 79.07M | 59.73M | -972K |
Mar 2024 | -32.79M | -243.24M | 175.67M |
Immatics N.V. alternative data
Aug 2023 | 402 |
---|---|
Sep 2023 | 402 |
Oct 2023 | 210 |
Nov 2023 | 210 |
Dec 2023 | 433 |
Jan 2024 | 433 |
Feb 2024 | 433 |
Mar 2024 | 432 |
Apr 2024 | 432 |
May 2024 | 432 |
Jun 2024 | 432 |
Jul 2024 | 432 |
Immatics N.V. other data
Immatics: Pioneering TCR Therapies In The Fight Against Cancer
Analyzing Immatics' Multi-Faceted Investment Case
Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203
Immatics Is Increasingly Becoming Interesting
Volume Breakout Report Update: Buy Eton Pharmaceuticals
Volume Breakout Report: August 6, 2022 (Technical Analysis)
Volume Breakout Report: July 30, 2022 (Technical Analysis)
Volume Breakout Report: July 23, 2022 (Technical Analysis)
Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
-
What's the price of Immatics N.V. stock today?
One share of Immatics N.V. stock can currently be purchased for approximately $5.7.
-
When is Immatics N.V.'s next earnings date?
Unfortunately, Immatics N.V.'s (IMTX) next earnings date is currently unknown.
-
Does Immatics N.V. pay dividends?
No, Immatics N.V. does not pay dividends.
-
How much money does Immatics N.V. make?
Immatics N.V. has a market capitalization of 828.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 68.76% to 54M US dollars.
-
What is Immatics N.V.'s stock symbol?
Immatics N.V. is traded on the NASDAQ under the ticker symbol "IMTX".
-
What is Immatics N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immatics N.V.?
Shares of Immatics N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Immatics N.V. have?
As Jul 2024, Immatics N.V. employs 432 workers.
-
When Immatics N.V. went public?
Immatics N.V. is publicly traded company for more then 6 years since IPO on 12 Dec 2018.
-
What is Immatics N.V.'s official website?
The official website for Immatics N.V. is immatics.com.
-
How can i contact Immatics N.V.?
Immatics N.V. can be reached via phone at +49 7071 53970.
Immatics N.V. company profile:

Immatics N.V.
immatics.comNASDAQ
542
Biotechnology
Healthcare
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Tübingen, 72076
CIK: 0001809196
ISIN: NL0015285941
CUSIP: N44445109